The Journal of Thoracic and Cardiovascular Surgery
Volume 124, Issue 3 , Pages 435-441 , September 2002

The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease

Received 7 May 2001 ,Revised 28 September 2001 ,Accepted 31 October 2001.

References 

  1. Bando K, Turrentine MW, Sharp TG, et al.  Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996;112:1600–1609
  2. Schulze-Neick I, Penny DJ, Rigby ML, et al.  L-Arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation. 1999;100:749–755
  3. Kirshbom PM, Page SO, Jacobs MT, et al.  Cardiopulmonary bypass and circulatory arrest increase endothelin-1 production and receptor expression in the lung. J Thorac Cardiovasc Surg. 1997;113:777–783
  4. Komai H, Adatia IT, Elliott MJ, et al.  Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 1993;106:473–478
  5. Bando K, Vijayaraghavan P, Turrentine MW, et al.  Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation. 1997;96:II-346–II-351
  6. Petrossian E, Parry AJ, Reddy VM, et al.  Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow. J Thorac Cardiovasc Surg. 1999;117:314–323
  7. Battistini B, Dussault P. Blocking of the endothelin system: the development of receptor antagonists. Pulm Pharmacol Ther. 1998;11:97–112
  8. Takeoka M, Ishizaki T, Sakai A, et al.  Effect of BQ13 on vasoconstriction as a result of either hypoxia or endothlin-1 in perfused rat lungs. Acta Physiol Scand. 1995;155:53–60
  9. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ. Short-term haemodynamic effects of BQ-123, a selective endothelin (ET9A)-receptor antagonist in chronic heart failure. Lancet. 1998;352:201–202
  10. Naik SK, Knight A, Elliott MJ. A successful modification of ultrafiltration for cardiopulmonary bypass in children. Perfusion. 1991;6:41–50
  11. Davies EE. Respiratory mass spectrometry: ‘on line’ computer control and data processing. J Physiol (Lond. 1973;231:80P–81P
  12. Shekerdemian LS, Shore DF, Lincoln C, et al.  Negative-pressure ventilation improves cardiac output after right heart surgery. Circulation. 1996;94:II-49–II-55
  13. Kojima T, Isozaki-Fukuda Y, Takedatsu M, et al.  Plasma endothelin-1 like immunoreactivity levels in neonates. Eur J Pediatr. 1992;151:913–915
  14. Voelkel NF, Cool C, Lee SD, et al.  Primary pulmonary hypertension between inflammation and cancer. Chest. 1998;114:225S–230S
  15. Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest. 1998;114:237S–241S
  16. Stewart DJ. Endothelial dysfunction in pulmonary vascular disorders. Arzneimittelforschung. 1994;44:451–454
  17. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:440–446
  18. Wessel DL, Adatia I, Giglia TM, et al.  Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993;88:2128–2138
  19. Roberts JD, Polaner DM, Lang P, et al.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:818–819
  20. Rossaint R, Falke KJ, Lopez F, et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;238:399–405
  21. Kinsella JP, Schmidt JM, Griebel J, et al.  Inhaled nitric oxide treatment for stabilization and emergency medical transport of critically ill newborns and infants. Pediatrics. 1995;95:773–776
  22. Sonntag J, Dahnert I, Stiller B, et al.  Complement and contact activation during cardiovascular operations in infants. Ann Thorac Surg. 1998;65:525–531
  23. Shafique T, Sellke FW, Thurer RL, et al.  Cardiopulmonary bypass and pulmonary thromboxane generation. Ann Thorac Surg. 1993;55:724–728
  24. Dupuis J, Stewart DJ, Cernacek P, et al.  Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94:1578–1584
  25. Ray SG, McMurray JJ, Morton JJ, et al.  Circulating endothelin is not extracted by the pulmonary circulation in man. Chest. 1992;102:1143–1144
  26. Eaton GM, Bush CA, VanFossen DB, et al.  Absence of pulmonary endothelin gradient in patients with normal or elevated circulating endothelin. Am J Cardiol. 1994;73:1015–1016
  27. Kobayshi T, Miyauchi T, Sakai S, et al.  Down-regulation of ET(B) receptor, but not ET(A) receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1?. Life Sci. 1998;62:185–193
  28. Dupuis J, Rouleau JL, Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation. 1998;98:1684–1687
  29. Langleben D, DeMarchie M, Laporta D, et al.  Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;148:1646–1650
  30. Macdonald PD, Paton RD, Logan RW, et al.  Endothelin-1 levels in infants with pulmonary hypertension receiving extracorporeal membrane oxygenation. J Perinat Med. 1999;27:216–220
  31. Allen SW, Chatfield BA, Koppenhafer SA, et al.  Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis. 1993;148:519–522
  32. Cacoub P, Dorent R, Nataf P, et al.  Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res. 1997;33:196–200
  33. Giaid A, Yanagisawa M, Langleben D, et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739
  34. D'Amico M, Berrino L, Filippelli A, et al.  Relation between L-arginine-nitric oxide pathway and endothelin-1 effects in periaqueductal gray area of rats. J Cardiovasc Pharmacol. 1994;24:974–978
  35. Naline E, Bertrand C, Biyah K, et al.  Modulation of ET-1-induced contraction of human bronchi by airway epithelium-dependent nitric oxide release via ET(A) receptor activation. Br J Pharmacol. 1999;126:529–535

☆ This work was made possible by a grant from the National Heart Research Fund (No. 99-CC-10), Leeds, United Kingdom.

☆☆ Address for reprints: D. J. Penny, MD, Cardiology Department, Royal Children's Hospital, Flemington Rd, Parkville, Victoria 3052, Australia (E-mail: pennyd@cryptic.rch.unimelb.edu.au).

PII: S0022-5223(02)00104-6

doi: 10.1067/mtc.2002.121492

The Journal of Thoracic and Cardiovascular Surgery
Volume 124, Issue 3 , Pages 435-441 , September 2002

Article Tools

* Image Usage & Resolution